Mitsubishi Tanabe Pharma

Mitsubishi Tanabe Pharma Corporation
FY2010 Business Results
Progress of the Development Pipeline

May 12, 2011

Nomura conference plaza Nihonbashi

Seiichi Murakami
Division Manager of Development Division

Agenda

1. Development Pipeline Status
2. Major Development Pipeline
    - Overseas Development Status
    - Domestic Development Status
    - Early Development Status
    - Others

Mitsubishi Tanabe Pharma

1. Development Pipeline Status

Development Pipeline Status <Japan>

Changes since announcement of Financial Results for FY2010 (29 Oct., 2010)



*;Systemic Vasculitis, systemic lupus erythematosus, polymyositis, dermatomyositis, scleroderma, mixed connective tissue disease, intractable rheumatic disease

**;for suppression of immunization of the D(Rho) factor (post partum, treatment through pregnancy or for parturition, abdominal bruise etc., and pregnancy around 28 weeks

★;the Review Committee on Unapproved Drugs and Indications with High Medical Needs

In-house developments, licensed products <Overseas>

Mitsubishi Tanabe Pharma

Changes since announcement of Financial Results for FY2010 (29 Oct., 2010)

: Stage Up

Overseas (in-house development products)

Phase 1	Phase 2	Phase 3	Filed
MP-124 (Stroke)	MCI-186 (Stroke)	MCI-196 (Hyperphosphatemia)	
MP-136 (Dyslipidemia)	MP-513 (Type 2 Diabetes Mellitus)	MP-146 (Chronic Kidney Disease)	
TA-8995 (Dyslipidemia)	MT-2832 (Secondary Hyperparathyroidism)		
MT-3995 (Hypertention)			
MP-157 (Hypertention)			
MT-1303 (Multiple Sclerosis)			
GB-1057 (Stabilizing Agent)			

Agree to approval

Argatroban * (Dialysis, HIT)

Approved

Lisensed out product

FTY720 (Multiple Sclerosis) EU

Overseas (main licensed products)

	Phase 2	Phase 3	Filed
Metabolism/ Cardiovascular	TA-7284 (Obesity)	TA-7284 (Type 2 Diabetes Mellitus)	TA-1790 (Korea) (Erectile Dysfunction)
Immunology	T-0047 (Multiple Sclerosis)	TA-1790 (US) (Erectile Dysfunction)	
CNS			
Others			

*;France, Spain

Mitsubishi Tanabe Pharma

2. Major Development Pipeline

Development Status

Mitsubishi Tanabe Pharma



Mitsubishi Tanabe Pharma

2. Major Development Pipeline
Overseas Development Status

MCI-196 (Hyperphosphatemia)

Mitsubishi Tanabe Pharma

【Development Status】 Phase3, preparing for European MAA





Mitsubishi Tanabe Pharma

2. Major Development Pipeline
Domestic Development Status

Remicade (Life Cycle Management)

Mitsubishi Tanabe Pharma

Changes since announcement of Financial Results for FY2010 (29 Oct., 2010)

: Stage up



CD: Crohn's disease
RA: Rheumatoid arthritis
BD: Behcet's disease (uveoretinitis)
AS: Ankylosing spondylitis
UC: Ulcerative colitis

Approved
Applied
Development request

*1 ; Nerves, intestinal tract, vascular BD
*2 ; refractory of IVIG

FTY720 Clinical Trial Results in Overseas

FREEDOMS

Annualized relapse rate



Gd-enhancing lesions on T1 weighed images



Primary endpoint： Annualized relapse rate
Secondary endpoints：Features on MRI（Gd enhancing lesions etc.）

Kappos, L. et al. N. Engl. J. Med., 362, 387 (2010)

FTY720 Clinical Trial Results in Japan

Mitsubishi Tanabe Pharma

【Development status】 Filed in December, 2010
【Target Indication】 Multiple Sclerosis
【Study design】 six months administration, Double-blind study (Phase2)

Patients free from Gd enhancing lesions ration in at both 3M/6M points in time



Annualized relapse rate



Primary endpoint ：Features on MRI（Gd T1 enhancing lesions）
Secondary endpoints： Annualized relapse ration etc.

Mitsubishi Tanabe Pharma

2. Major Development Pipeline
Early Development Status

MT-1303 (multiple sclerosis)

Mitsubishi Tanabe Pharma

【Development Concept】

Successor of FTY720

【Mechanism of Action】

Sphingosine 1 phosphate receptor modulator

【Target Indication】

Multiple sclerosis

【Development Plan】

Phase1 in Europe

MT -3995 (hypertension)

Mitsubishi Tanabe Pharma

【Development Concept】

New mineral corticoid receptor antagonist

- enough control for daytime and nighttime hypertension, and decrease AE related with sexual hormone balance and DDI effects

【Mechanism of Action】

Selective mineral corticoid receptor antagonist

【Target Indication】

Hypertension

【Development Plan】

Phase1 in Europe

Cautionary Statement

The statements contained in this presentation is based on a number of assumptions and belief in light of the information currently available to management of the company and is subject to significant risks and uncertainties. Actual financial results may differ materially from these forecasts depending on a number of important factors.